Amishi Y. Shah

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Jianjun Gao, Neema Navai, Omar Alhalabi et al. · Nature Medicine · 2020 · 300 citations · Full text

Surgical Oncology, Urology, Genitourinary Cancer +7

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Robert J. Motzer, Thomas Powles, Mauricio Burotto et al. · The Lancet Oncology · 2022 · 286 citations · Full text

Urology, Genitourinary Cancer, Medicine +10

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Chung‐Han Lee, Amishi Y. Shah, Drew Rasco et al. · The Lancet Oncology · 2021 · 178 citations · Full text

Urology, Genitourinary Cancer, Study 111/Keynote-146 +8

Distinct Roles for the p110α and hVPS34 Phosphatidylinositol 3′-Kinases in Vesicular Trafficking, Regulation of the Actin Cytoskeleton, and Mitogenesis

Uma Siddhanta, James McIlroy, Amishi Y. Shah et al. · The Journal of Cell Biology · 1998 · 149 citations · Full text